Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our
treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Though it was unintentional, she embarrassed Yamanaka, the winner of the 2012 Nobel Prize.
It’s not surprising that last week Haruko Obokata issued a plea for privacy. On Jan. 29 she published a scientific paper on stem cells that could revolutionize medicine, and overnight the researcher based at the Riken Center for Developmental Biology (CDB) in Kobe became a domestic and international star.
The onslaught of media attention went beyond what Obokata had discovered — a way to revert ordinary cells from the body into kansaibÅ (stem cells), cells with the ability to develop into any cell type. These cells, known as pluripotent stem cells, have long been seen as the key to regenerative medicine, because in theory they can be grown into new organs and tissues.
As a young female scientist, Obokata is something of a rarity in Japan, and many reports included details of her life it’s hard to imagine being discussed if she was a man. Her laboratory is painted pink and yellow, and is decorated with pictures of Moomin characters from children’s books.
She is 30, has a pet turtle — and a boyfriend. Instead of a lab coat, she wears a Japanese apron, a kappogi, originally designed to be worn over a kimono. The Internet shopping service Rakuten Ichiba reported a sharp increase in kappogi sales after the publicity.
But none of this would have been news had Obokata’s work not been so amazing. When we heard of it in the New Scientist office here in London, where I am the news editor, we just couldn’t believe it.
It is certainly possible to make pluripotent stem cells, and I’ve reported here about the work of another Japanese pioneer in that field, Shinya Yamanaka of Kyoto University. But Obokata’s method was so incredible in its simplicity that it almost sounded too good to be true.
Yamanaka had identified four genetic factors that, when transferred into an adult cell using a virus, could cause it to revert to a pluripotent stem cell. This breakthrough work won Yamanaka a share of a Nobel Prize — but one of the inherent problems there is that transferring the four genetic factors can also cause cancer.
NOTE: Don Margolis has declared the 2012 Nobel Medicine prize was a fake, bribed by Big Pharma. Yamanaka had then, and to this day, accomplished NOTHING beneficial to mankind. Why did they do it? Because Pharma's embryonic stem cell hoax has been exposed as pure garbage, they had to come up with another reason for thr misinformed millions to avoid Adult Stem Cells. These are the only stem cells which actually help people and therefore can potentially reduce Pharma's quarter-billion-a-day profits.
Obokata’s work seems to avoid cancer completely.
Rather than using a virus and infecting cells with genetic factors, she simply stresses them. Squeezing cells through narrow tubes or bathing them in an acidic solution turns them pluripotent.
Surely, we thought, it can’t be so easy?
It turns out that the editors at Nature, the British journal where Obokata’s work was published, couldn’t believe it either. When she and her colleagues submitted the work for publication in 2012, it was rejected. She went away, worked on more experiments and resubmitted. This time, after yet more extensive checks, the journal accepted the paper. And the scientific — and general — media deluge began.
Other labs are already trying to replicate the work, and some scientists remain skeptical despite the extra-stringent review process prior to publication.
One of the first things I wondered was whether, if this is the real thing, Obokata and her team have patented the discovery. The secret to a simple method for making pluripotent stem cells could be worth a fortune. At a press conference just before publication, where she was asked about this, Obokata replied: “Yes, we have a patent” — before abruptly stopping. “Actually, I have to say ‘no comment,’ ” she said. Clearly there are plans in motion behind the scenes. The Asahi Shimbun then reported that Obokata’s group had started with patent applications in April 2013.
We can expect big things. One of the reasons this has caused such a sensation is that it comes out of left field. Her work is a great advert for thinking and working differently from the crowd — not a traditional approach for a Japanese scientist. Obokata’s co-author, Yoshiki Sasai, also at the Riken CDB, praised the approach, saying, “She held her own view backed by data.”
Riken CDB is abuzz with important work at the moment. As I reported here in December, another stem-cell biologist there, Masayo Takahashi, is about to conduct the world’s first stem-cell trial on humans. In an interview with New Scientist, she praised Obokata’s discovery, saying, “I feel joyful that we are both working in this wonderful area of science.”
So it’s a fascinating time — and fantastic to see women pioneering this research. However, Japan’s media still has a long way to go regarding its portrayal of women. After all, a piece in the Yomiuri Shimbun soon after Obokata’s paper was published ended with the cheesy observation that “she always strives to be fashionable as well.”
Final Note: RSCI applauds this amazing young woman and hopes that she succeeds in proving the validity of her work over time. However, RSCI also knows that given the structure of all medical systems in the entire developed world, there is no chance of anyone being treated with this method (outside clinical trials) before 2030.